SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

This study is for people who have recently been diagnosed with Type 1 Diabetes. To be considered, you should be between 5 and 40 years old and have received your diagnosis no more than 100 days before the study starts. If you were initially told you had Type 2 Diabetes but were later diagnosed with Type 1, the 100-day limit still applies from that first diagnosis date.

You also need to meet certain health requirements. For example, your body must still be making a certain level of natural insulin, which will be checked through a blood test. Doctors will also need to confirm your Type 1 Diabetes diagnosis using specific markers in your blood.

It's important that you, or your legal guardian if you're under 18, understand everything about the study and agree to participate. Female participants must be unable to become pregnant (for example, if they have undergone certain medical procedures or are past menopause), or be prepubescent.

If you decide to take part, you'll be assigned to one of three groups by chance: a high dose of SAB-142, a low dose of SAB-142, or a placebo (a dummy drug). You, or your child, will receive the study treatment, and the study team will ask you to visit the clinic regularly. During these visits, doctors will perform various checks, including blood tests and other assessments, to see how the treatment is affecting you and to monitor your overall health.

Throughout the study, you'll be closely monitored for any side effects or changes in your health. The duration of your participation will involve these regular visits and follow-up appointments. More details on the exact number and timing of visits would be provided by the study team, along with information about how long you'd be receiving the study medication and how long the follow-up period would be.